



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ :

A61N 1/30

A1

(11) International Publication Number:

WO 99/40967

(43) International Publication Date:

19 August 1999 (19.08.99)

(21) International Application Number: PCT/IL99/00077

(22) International Filing Date: 5 February 1999 (05.02.99)

(30) Priority Data:
123290 13 February 1998 (13.02.98) IL

(71) Applicants (for all designated States except US): HADA-SIT MEDICAL RESEARCH SERVICES & DEVELOPMENT COMPANY LTD. [IL/IL]; Kiryat Hadassah, P.O. Box 12000, 91120 Jerusalem (IL). YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM [IL/IL]; Jabotinsky Street 46, 92182 Jerusalem (IL).

(72) Inventors; and

(75) Inventors/Applicants (for US only): DOMB, Abraham [IL/IL]; Migdal Eder 16, 90435 Efrat (IL). FRUCHT-PERY, Joseph [IL/IL]; Hakalanit Street 67, 93848 Mevasseret Zion (IL). SHAPIRO, Mervyn [IL/IL]; Tel-Chai Street 7, 92107 Jerusalem (IL).

(74) Agent: REINHOLD COHN AND PARTNERS; P.O. Box 4060, 61040 Tel Aviv (IL).


(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: A DEVICE FOR IONTOPHORETIC ADMINISTRATION OF DRUGS



(57) Abstract

The present invention concerns a device (10) for administration of charged drugs to the eye comprising an applicator with a receiving portion for holding a hydrogel carrier loaded with the drug. The device also comprises an electric current generating element (15, 13, 14) for generating currents not exceeding 1000 μ Amp coupled to a timing element (11) which ensures that currents do not last more than 120 secs.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States-party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

A DEVICE FOR IONTOPHORETIC ADMINISTRATION OF DRUGS

FIELD OF THE INVENTION

The present invention concerns a device for iontophoretic administration of drugs and more particularly to administration of drugs to the eye.

5

BACKGROUND OF THE INVENTION

The introduction of various drugs to the cornea of the eye, for example, administration of antibiotics for the treatment of microbial keratitis, is a complicated procedure. Presently, the routine treatment of microbial
10 keratitis (MK) includes topical administration of highly concentrated antibiotics every 30 to 60 minutes day and night for several days. It should be noted that the bioavailability of a drug when administered in eye drops is very low (less than 1% of the administered dose) due to continuous rinsing of the drug by the tears.

15

An alternative method of administration of drugs is, by subconjunctival injections of antibiotics several times a day into the eye. The injections require a physician, are very painful and may cause severe complications such as perforation of the globe and scarring of the conjunctiva. Systematic administration of antibiotics is not effective in a vascular cornea.

Thus, there has been a constant search for development of alternative delivery techniques for overcoming the existing problems of administration of drugs to the eye. Some encouraging studies indicate efficacy of use of contact lenses soaked with highly concentrated antibiotics. However, these lenses may not be tolerable by patients with MK who commonly have inflamed and swollen conjunctiva and eye lids. There also have been some trials with liposomes incorporated with medicaments and use of laser, but these trials did not gain significant clinical acceptance.

Iontophoresis (INT) is a noninvasive method which allows penetration of high concentrations of ionized molecules, such as drugs, into the tissue with the help of an electric current. In the past this method was utilized for anesthesia, for myringectomy, for diagnostic sweat testing in patients with cystic fibrosis and for administration of vidarabine in cases of herpes simplex. The drugs administered were steroids, antibiotics, peptides and analgesics. In ophthalmology, iontophoresis had been experimentally used in several animal studies to evaluate its efficacy in concentrating the drugs into the cornea or the eye. Barza⁽¹⁾ showed that transscleral INT using solutions may induce bactericidal concentrations of gentamicin (for several hours) in the vitreous of the monkey eye. Furthermore, repeated Electro Retino Graphia (ERG) tests did not show damage to the retina. Similar studies in the rabbit eyes presented high concentrations of gentamicin, cefazoline and ticarcillin in the vitreous⁽²⁾. Iontophoresis was also efficient for treatment of microbial endophthalmitis in the rabbit eye. It has been reported⁽³⁾ that INT of tobramycin was more effective than topical administration of tobramycin for experimentally induced keratitis in the rabbit eye. INT of gentamicin via the cornea in aphakic rabbit eye revealed high levels of gentamicin in the vitreous. Finally, INT increased the penetration of ketaconazole (an antifungal drug) into the animals' anterior chamber⁽⁴⁾.

The major limitations of INT in all prior art reports and trials were in the use of drug solutions which required complicated design of instruments needed in order to keep the fluid drug solution in contact with the desired tissue during the process of the iontophoresis. Handling of fluids to ensure their contact with a desired tissue is tricky, since the fluids leak, and form bubbles that reduce the efficacy of iontophoretic process.

Another approach to iontophoretic administration of drugs to the eye was described by Grossman, who reported that marked concentrations of gentamicin can be transferred into the rabbit cornea by INT when the drug gentamicin was incorporated in soft agar gel (instead of in a liquid solution)^(5,6). However, the use of agar has major limitations as follows: agar is a biologic material, so that each batch preparation of the agar results in slightly different products causing problems in the reproducibility of the drug administration; the shelf life of agar is very limited, it has to be kept in a refrigerated and moist environment rendering it impractical for prolonged storage; agar is fragile and requires expertise to be placed directly in contact with the ocular surface without breaking; and finally some of the agar material will always stay on the ocular surface, causing irritation, eye redness and inflammation.

It would have been highly desirable to provide a device for iontophoretic administration of drugs to the eye which would be easy to operate, safe and would minimize damage to the eye.

SUMMARY OF THE INVENTION

The present invention concerns a device for iontophoretic administration of charged drugs to the eye comprising:

- an applicator formed with a receiving portion adapted for holding a replaceable hydrogel carrier loaded with said drug and allowing contact of the carrier with a surface of the eye;

- an electric current generating element, for generating currents not higher than about 1000 μ Amp, being electrically coupled to the said receiving portion such that the current once generated passes through the hydrogel carrier in a direction essentially normal to said surface;
- 5 - a timing element for activating the electrical current generating element for pre-set periods of time not exceeding 120 seconds; and
- a switch for activating said timing device.

The device of the present invention is suitable for safe administration of iontophoretic drugs into the eye which do not exceed pre-set
10 periods, and do not exceed maximum level of electric current. The device of the invention enables safe reproducible and repeated administration of drugs to the eye.

The term "*charged drugs*" refers to drugs which may be *a priori* charged, to the drugs which become charged in a solution with which the
15 hydrogel carrier is loaded, as well as to drugs which are initially not charged, but become charged in the presence of an electrical current.

Examples of commonly used charged drugs include antibiotics such as: gentamicin, tobramycin, vancomycin; antifungal drugs including: miconazole, ketoconazole; anti-inflammatory agents such as: ibuprofen and its
20 derivatives; timolol; steroids; anti glaucoma agents such as: pilocarpine; anticancer agents such as mitomycin C, methotrexate and 5-FU which are delivered to treat cancer of the eye or cornea; local anesthetics which are delivered to the eye and to the conjunctiva to anesthetize the eye before a treatment or reduce pain, such as lidocaine, bupivacaine and benoxinate.

25 The term "*eye*" refers to the external regions of the eyes and includes the cornea, conjunctiva, sclera, eye lids and lid margins.

The device comprises an applicator having a receiving portion which can hold a replaceable hydrogel carrier, that is loaded with the drug. The applicator is in the form which allows contact of the carrier and the surface of

the eye. The applicator may be held by a specific external fixing device, for example, during an operation to ensure its position, but preferably, for ease of operation it should be hand held. The applicator may form a separate component of the device of the invention, or alternatively, the whole device of the invention may be in the form of a single instrument wherein the applicator is an integral part thereof.

The applicator has a receiving portion, for example in the form of an indentation, or in the shape of a half-circle ring for holding a replaceable hydrogel carrier which is loaded with the drug. Preferably the indentation is conical or cylindrical to accommodate a hydrogel carrier having a corresponding shape. Typically, the applicator or the whole device (when applicator is integral with the device) is in the shape of an elongated rod where the receiving portion is at the end of the rod.

The device includes an electrical current generating element which can be battery operated or connected to an external AC power source, for the generation of currents which are not higher than about 1000 μ Amp. The electrical current generating element is positioned so that it is electrically coupled to said receiving portion. In operation, when a hydrogel carrier is fitted within the receiving portion, the electrical current generating element, generate currents that pass through the hydrogel in a direction substantially normal to the surface of the eye, thus causing the migration of charged drugs from the hydrogel carrier to the eye. both due to electrical field as well as due to diffusion. Preferably, the device should also comprise an electric control element which can control the level of the current passed into the gel to a pre-set current. For example, the physician may decide to apply a current of a specific level by properly adjusting the control element.

The device should also include a timing device for activating the electrical current generating element for pre-set periods of time not exceeding 120 seconds. Thus in operation, the physician or the patient itself, may choose

a preset period of time, and a pre-set level of electric current (by adjusting the electric control element), and by mere activation of the switch, produce an electrical current of a fixed duration and level.

Where the device of the invention is battery operated, and the
5 device is in the shape of an instrument having an applicator integral therewith, the device should also contain a recess for holding the battery.

The ground element of the device, may be in the form of a separate wire extending externally from the applicator, which can be in touch with any part of the patient's body, preferably on his face, to serve as ground.

10 By another aspect, the present invention concerns a system for iontophoretic administration of drugs to the eyes, comprising a device as described above, and a drug loaded hydrogel carrier which carrier has a shape and size so as to be accommodated by the receiving portion of said device. For example, where the receiving portion is conical or cylindrical, the carrier is in
15 the form of conic or cylindric disc, respectively, having a size which precisely matches that of the receiving portion. Where the receiving portion is in the shape of a half ring the carrier is in the shape of a round disc. Preferably, the calibration size of the carrier should be in the size range of 0.2 mm (for administration to small regions of the eye) to about 20 mm, (for example, for
20 administration to the whole region of the eye in larger animals such as cattle).

It is also possible to produce a system for iontophoretic administration of the eye, wherein the receiving portion is adjustable, so it can receive various hydrogel carriers of various sizes, so that a single applicator is suitable for many sizes of hydrogel carriers, for example the receiving portion
25 may include a ring with an adjustable diameter which holds the carrier.

By a third aspect, the invention concerns a hydrogel carrier for use in the above system, comprising a hydrogel material having at least 50% w/w water content; the hydrogel carrier being impregnated with the charged

drug. Typically, the hydrogel carrier should be in the shape of a conical or cylindrical disc.

The hydrogel material that is suitable for this application should contain at least 50% w/w of water to allow free transport of the drug through the gel; it should be compatible with the eye; be inert to the loaded drug and safe at storage and during application should not release any unwanted small irritating/toxic molecules; stable during the life of the application; it should be physically and chemically stable in order to maintain its shape and size and its chemical and physical integrity; and generally should be comfortable in contact with the eye.

The hydrogel material is typically uncharged but may contain anionic (carboxylates) or cationic (amino groups) residues to enhance drug release upon application of a current pulse. The hydrogel may contain other organic or inorganic ions and salt solutions. Hydrogel discs are prepared from various known hydrogel compositions including: acrylic based hydrophilic monomers, crosslinked, polysaccharides and polyols, and crosslinked polyethylene glycols. Various compositions of hydrogels are described in the literature⁽⁷⁾.

The charged drugs are loaded into the hydrogel carrier either during the preparation of the gel (for example during the polymerization process) or by placing a pre-prepared carrier pellet in a drug solution so that the gel absorbs the solution.

The present invention further concerns a method for the administration of charged drugs to the eye comprising:

- (i) contacting a substance of the eye with a hydrogel carrier impregnated with said drug;

(ii) passing a current through said carrier at an intensity below about 1000 μ Amp for a period not exceeding 120 seconds and in a direction normal to said surface, thereby causing the charged drug to migrate from said carrier to the eye.

5 Preferably the method should make use of the system of the invention. The method is suitable for medicinal and veterinary purposes.

In the following, the invention will be further described with reference to some non-limiting drawings and examples.

10 BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 shows a schematic representation of the electronic components of the device of the invention; and

Fig. 2 shows a schematic representation of the device of the invention.

15 DETAILED DESCRIPTION OF THE INVENTION

Reference is now made to Fig. 1 which schematically shows the main electronic component of the device of the invention 10. The device is composed of an O.S. timer 11 connected to adjustable component 12 for adjusting the time between 10 and 120 seconds.

20 The timer is electrically coupled to a resistor of 9 K 13 which is in-line coupled with an adjustable resistor of 90 K 14, which adjustable resistor can tune the current between 100 and 1,000 μ Ampere.

The electronic components are powered by a power source 15, for example a battery, and is the electronic circuitry activated by switch 16.

25 The hydrogel disk 17 is connected to the cathode end of the electronic component 18 while the anode 19 has a wire 20 extending therefrom which is connectable to an external body surface other than the eye. In operation, the physician sets the desired current by adjustable resistor 14, sets the desired time by time tuning component 12, places disk 17 on eye 21,

and then closes switch 16 to activate the system. Meanwhile wire 20 is placed on an external part of the patient's body, for example, his ear, cheek, etc.

Reference is now made to Fig. 2, which shows a schematic representation of the device of the invention 30. The device has a receiving portion 31 composed of an L-shaped arm 32 extending from the body of the device, and an adjustable ring 33, which claps the hydrogel carrier 34. Ring 33 may accommodate hydrogel carrier discs of various dimensions, by adjusting, with screw 35, the diameter of the ring.

The container of the device 36, holds the electronic components shown schematically in Fig. 1. More specifically, it has an on/off switch 37, and a push button 38 (corresponding essentially to electronic component 16 in Fig. 1), which when touched gives pulses of a pre-set length and magnitude.

The device has a time control button 39 (corresponding essentially to electronic component 12) and a digital time display window 40, and a current control button 41 (corresponding to component 14 in the electronic circuitry) and a digital current display window 42.

The anode of the device is connected to wire 43.

In operation, hydrogel 34 is placed on eye 44, and wire 43 is placed on any external part of the patient, for example, the ear, cheek, in his mouth, etc.

I. PREPARATION OF POLYMERIC HYDROGELS

Example 1 Preparation of disposable hydrogel loaded with gentamicin

The hydrogels were prepared by polymerization of solutions containing methylmethacrylate (MMA, 0-10%), hydroxyethylmethacrylate (HEMA, 3-50%), ethyleneglycol dimethacrylate (EGDMA, 0-5%), gentamicin (0-20%), water (20-95%) and a radical source (redox mixture, $\text{Na}_2\text{S}_2\text{O}_5$ and $\text{Na}_2\text{S}_2\text{O}_8$.) The solutions were cast between two flat glasses to form a film or

into conic vials and polymerized at room temperature overnight. The polymerized gels were cut into the appropriate size to fit the end of a probe.

Gentamicin was loaded into the gel either during polymerization of the monomer or by absorption from a 10% aqueous solution of gentamicin.

5 Other useful uncharged monomers which may be used are acrylamide and its derivatives, N,N-ethylenediacrylamide, glycerol methacrylate, and N-vinylpyrrolidone. Charged monomers are methacrylic and acrylic acid, aminoethylmethacrylates, vinylpyridines and vinylimidazoles.

In a typical preparation, HEMA (2.0 ml), EGDMA (0.04 ml),
10 gentamicin sulfate (100 mg), water (2.0 ml) and a redox mixture of 2% w/v $\text{Na}_2\text{S}_2\text{O}_8$ (0.05 ml) and 2% w/v $\text{Na}_2\text{S}_2\text{O}_5$ (0.05 ml) are mixed to form a uniform solution. The solution was purged with dry nitrogen and then cast in between two flat glasses separated with a gasket of 2 mm and left to polymerize overnight at room temperature. The solid membrane was cut into circular discs
15 of 3 mm in diameter.

Alternatively, the same polymer composition was prepared but without the drug and cast into a solid membrane of 2 mm thick. The membrane was cut into discs and the discs were dehydrated by lyophilization. The dried discs were allowed to hydrate into a 10% w/v gentamicin sulfate solution for 24
20 hours at room temperature. The hydrated discs were blotted with a sterile tissue prior to use.

Example 2 Preparation of polysaccharide gels:

a. Albumin cross linking oxidized Arabinogalactan (AG)

25 Albumin, a natural compatible protein containing amine groups, was reacted with increasing amounts of oxidized AG in order to obtain a cross-linked gel. The experiment was as follows: 1.0 gr. of egg-albumin (or bovine serum Albumin) was dissolved in 5.0 ml of 0.1 M NaHCO_3 , the solution was incubated for 15 min. at 37°C to obtain a clear-yellow solution

which was reacted with a concentrated solution of oxidized AG (1.0 g in a 2 ml solution) for 24 hours at 37°C to form an insoluble gel. Other proteins such as gelatin, chitosan, and collagen were also used instead of albumin.

5 b. Lysine cross linking with oxidized Arabinogalactan

1.0 g of di-aldehyde Arabinogalactan (35% degree of oxidation) was dissolved in 4.0 ml deionized water and 25 mg of lysine hydrochloride was added to the polymer solution and the pH was adjusted to 8.0 using 0.1M NaOH solution. Under these conditions cross linking is fast. At the alkaline pH
10 of the water phase, reaction of lysine with di-aldehyde Arabinogalactan proceeds rapidly and the gel hardened. The obtained gel was washed with water several times to remove soluble matters and dried in vacuum (yield = ~ 90% by weight).

Reduction of the Imine-bond obtained in the gel was done by
15 incubating the gel in sodium borohydride solution (1.5 mol NaBH₄ for each 1 mol sugar units of polysaccharide) for 4 hours at room temperature followed by filtration and washing with water. The reduced gel was placed in ethanol at 4°C overnight, isolated and dried in vacuum. Gels with increased cross linking were obtained by reacting the oxidized polysaccharide with increasing amounts
20 of lysine up to about 20% by weight per polymer. Other diamine molecules such as ethylene diamine, hexamethylene diamine and polyethylene imine can be used instead of lysine.

The dry gel was loaded with gentamicin by immersing the gel in a 10% gentamicin sulfite solution for 24 hours.

25

Example 3 Preparation of polyurethane gels:

Polyurethane gel was prepared from Hypol PreMA G-60 (Hampshire Chem. Corp. Owensboro, KY, USA) which is a reactive diisocyanate). The gel film was prepared by diluting the viscous Hypol in

acetone (1 part in 2 parts) and then adding 2 parts of water. The solution was mixed well and the homogeneous solution was cast into a dye and allowed to solidify. The solution was solidified within 15 mins. and the polymerization was allowed to complete over night. The solid gel was placed in deionized water for 24 hours to extract impurities, cut into discs on 4x2 mm and then lyophilized. The clear and flexible dry discs were placed in a 10% by weight of gentamicin sulfate to absorb the solution and the hydrated gels were blotted with a paper tissue and weighed. The hydrated discs contained 92% of solution.

These discs are suitable for iontophoresis administration of gentamicin to the eye.

Example 4 Preparation of hydrogel pellets loaded with drugs:

Acrylic gel membranes prepared from cross-linked HEMA with 0.2-3% w/w of EGDMA or ethylenediacrylamide which absorb 85% of water.

The membranes were freeze-dried to dryness following drug absorption/loading by immersing the polymer discs in 10% drug solutions in aqueous solutions (i.e. buffer solutions, mixtures of water with hydrophilic solvents such as alcohol, DMSO, DMF and THF) overnight. Loading of 5 to 50 mg drug/ml hydrated gel was obtained. The following drugs were incorporated into the acrylate gel: ibuprofen, fluoprofen, timolol, miconazole, pilocarpine, tobramycin, vancomycin, and peptides including LHRH and TRH.

II. BIOLOGICAL TESTS

The release of gentamicin from hydrogel probes (prepared in Example 1 into rabbits' eyes) using iontophoresis was determined by the following two experiments:

Example 5 Release of gentamicin into the rabbit eye using hydrogel-probe iontophoresis:

Thirty six healthy rabbits (age 2-3 months, weight 2000 grams) were used. The study conformed with the ARVO Resolution of the Use of Animals in Research. The animals were anesthetized with intramuscular injections of ketamin HCl 1 mg/kg (Park Davis, Morris Plains, NJ) and xylazine 50 mg/kg (Mobay, Shawnee, KS). Iontophoresis was carried out as follows: the distal end of the hydrogel-probe placed in a device as shown in Fig. 2 (diameter of 3 mm and 2 mm thick) was gently applied to the cornea of the rabbit while the anode of the iontophoretic system is inserted into the other end of the device and the cathode is attached to the ear of the animal.

A single concentration of 10 mg/ml gentamicin in the hydrogel-probe (dd) was studied, using two time periods of iontophoresis: long periods (60 seconds) and short periods (10 seconds). Six groups of rabbits, 6 animals per group, were treated with one of the treatments described in the following Table 1.

Table 1

Group Number	Treatment	Gentamicin concentration in dd (mg/ml)	Current (mAmp)
1	60 sec. INT + drug	10	0.5
2	10 sec. INT + drug	10	0.5
3	20 drops.hr	0.3% drops	NA
4	60 sec. no current	10	0
5	10 sec. no current	10	0
6	60 sec. INT no drug	0	0.5

In group 3, one drop of topical gentamicin (14 mg/ml) was instilled into the eye every 5 minutes for 1 hour. In groups 4 and 5, mock iontophoresis was performed by placing a device containing 10 mg/ml of gentamicin on the cornea for 60 and 10 seconds without switching on the electric current. In group 6 iontophoresis was applied for 2 minutes with the dd
5 containing NaCl 0.9% (instead of gentamicin).

Ten minutes after completion of the iontophoresis, or the control drug delivery technique in each animal, the surface of the eye was washed with 5 ml of NaCl 0.9%. The animals were sacrificed after 15 minutes by injecting
10 an overdose of sodium pentobarbital. The entire cornea was excised with corneal scissors and rinsed again with 5 ml of NaCl 0.9%. The cornea was weighed, minced with a blade and placed into microcentrifuge tubes. To each tube, 0.5 ml 0.01 M phosphate buffered saline (pH 7.2) was added. The tubes were incubated for 18 hours in a water bath heated to 37°C, shaking at 100
15 oscillations/min. Thereafter the tubes were centrifuged for 10 min. at 2000 rpm. From each tube 125 microliter of the supernatant were assayed for gentamicin concentration using Abbot TD_x. The concentration of gentamicin in the cornea was calculated as described before⁽⁵⁾. Gentamicin concentrations are expressed in micrograms per gram of tissue or per milliliter of buffer. 3 way ANOVA test
20 was used for statistical evaluation.

The results are shown in the following Table 2.

Results:**Table 2 – Gentamicin concentration in the cornea after iontophoresis application**

5

Gentamicin concentration in cornea (mcg/g)

Eye No.	1	2	3	4	5	6	Average
Group No.							
1 (0.5 mA/60 sec)	32.0	24.6	53.3	30.7	28.0	30.0	33.1±9.3
2 (0.5 mA/10 sec)	6.27	6.53	4.92	6.70	7.05	7.52	6.5±0.8
3 (eye drops)	1.59	1.46	4.16	2.05	1.03	2.47	2.1±1.0
4 (0.0 mA/60 sec)	2.01	2.55	2.78	2.89	2.70	2.96	2.6±0.3
5 (0.0 mA/10 sec)	1.12	1.23	0.37	1.25	1.21	1.68	1.1±0.4
6 (0.0 mA/60 sec/ no drug), no irritation to the eye							0.0±0.0

Experiment 6

10 The purpose of this experiment was to determine the effect of the current applied and duration on the drug cornea concentration. In this experiment, 27 Albino rabbits were divided into 9 study groups as shown in Table 3. Each group of 3 rabbits (6 eyes) were treated with iontophoresis and the results are given in Table 4.

Table 3

Animal group design by: concentration of gentamicin in hydrogel probe
(dd), duration and current of iontophoresis

Group No.	Treatment	Gentamicin concentration in dd (mg/ml)	current (mAmp)
1	60 sec. INT	10	0.0
2	60 sec. INT	10	0.1
3	60 sec. INT	10	0.3
4	10 sec. INT	10	0.6
5	10 sec. INT	10	0.0
6	10 sec. INT	10	0.1
7	10 sec. INT	10	0.3
8	10 sec. INT	10	0.6
9	SC inj.	0.3% w/v	NA

5

Results

Table 4: Gentamicin concentration in the cornea after iontophoresis application – effect of time and current applied

Eye No.	1	2	3	4	5	6	Average
Group No.							
1 (0.0 mA/60 sec)	2.5	1.3	3.3	2.4	0	6.7	2.71±2.0
2 (0.1 mA/60 sec)	4.2	4.5	11.0	1.4	1.6	nd	4.5±3.5
3 (0.3 mA/60 sec)	18.3	34.4	87.4	14.1	56.7	nd	42.2±27.1
4 (0.6 mA/60 sec)	144.3	56.6	32.6	95.8	75.2	127.0	88.6±38.6
5 (0.0 mA/10 sec)	0.0	0.0	0.0	2.4	0.0	0.0	0.0
6 (0.1 mA/10 sec)	0.6	2.3	8.3	3.9	3.6	5.6	4.0±2.4
7 (0.3 mA/10 sec)	7.0	6.2	11.3	9.7	18.7	8.4	10.2±4.1
8 (0.6 mA/10 sec)	29.6	22.2	25.5	22.8	26.5	5.4	22.0±7.8
9 (subconj. inj.)	37.6	19.5	22.3	14.8	17.6	68.2	30±18.6

As can be seen, an increase in the gentamicin concentration is found with increase duration and amplitude of the electric current. Iontophoretic application using the hydrogel disc for 60 sec. at a 0.3 mAmp provided similar concentrations to the painful injection to the subconjunctiva (SC). Applying a current of 0.6 mAmp resulted in a 3 times increase in drug concentration as compared with SC injections and about 30 times over a non-current application (diffusion only). High gentamicin concentrations were found in the intraocular fluid for Groups 3 and 4.

Example 7: Toxicity and irritation studies:

HEMA based hydrogel discs with or without gentamicin were applied on the eye surface for up to 120 seconds and with an increasing current up to 1 mAmp. The eyes were isolated and evaluated histopathologically to determine any damage to the eye surface. No acute or long term damage to the eye or to the general health of the rabbits was found. The animals tolerated the devices and all tissues were normal and intact.

REFERENCES

1. Barza, M. *et al.*, *Inve. Ophthalmol. Vis. Sci.*, **154**:1033 (1987).
2. Barza, M., *et al.*, *Ophthalmology*, **93**:133 (1986).
3. Barza, M., *et al.*, *Inves. Ophthalmol. Vis. Sci.*, **28**:1033 (1987).
4. Grossman, R.E., *et al.*, *Ophthalmology*, **93**:133 (1986).
5. Grossman, R.E., *et al.*, *Inves. Ophthalmol. Vis. Sci.*, **31**:909 (1990).
6. Frucht Pery, J., *et al.*, *Inves. Ophthalmol. Vis. Sci. (Supp)*, 3914 (1993).
7. Dumitriu, S., *Polymeric Biomaterials*, (Editor) Marcel Dekker, NY. 3-85, (1993).

CLAIMS:

1. A device for iontophoretic administration of charged drugs to the eye comprising:
 - 5 - an applicator formed with a receiving portion adapted for holding a replaceable hydrogel carrier loaded with said drug and allowing contact of the carrier with a surface of the eye;
 - an electric current generating element, for generating currents not higher than about 1000 μ Amp, being electrically coupled to the said receiving portion such that the current once generated passes through the hydrogel carrier in a direction essentially normal to said surface;
 - 10 - a timing element for activating the electrical current generating element for pre-set periods of time not exceeding 120 seconds; and
 - a switch for activating said timing device.
- 15 2. A device according to Claim 1, wherein the applicator is hand held.
3. A device according to Claim 2 in the form of a hand held instrument with said applicator being integrally formed therein.
4. A device according to Claim 3, having the shape of an elongated member with the applicator formed at one end thereof.
- 20 5. A device according to any one of Claims 1 to 4, wherein the receiving portion is formed with an indentation for receiving a hydrogel carrier pellet.
6. A device according to Claim 5, wherein the indentation is adapted to receive a cylindrical hydrogel pellet.
- 25 7. A device according to any one of Claims 1 to 4, wherein the receiving portion is formed as a section of a ring or as a ring having an adjustable dimension.

8. A device according to any one of Claims 3 to 6, wherein the electric element is battery operated and the instrument includes a receptacle for holding batteries.

9. A device according to any one of Claims 1 to 8, having the ground element as a wire externally from the applicator.

10. A device according to any one of Claims 1 to 9, comprising an electric current control component for adjusting the level of electric current produced by the electric current generating element, to pre-set levels.

11. A system for the iontophoretic administration of drugs to the eye comprising a device according to any one of Claims 1 to 10, and a drug-loaded hydrogel carrier of a shape and size such so it may be accommodated within the receiving portion of said device.

12. A hydrogel carrier for use in the system of Claim 10, comprising hydrogel material having at least 50% w/w water content; said hydrogel carrier being impregnated with a charged drug.

13. A hydrogel carrier according to Claim 12, having the shape of a round disc.

14. A hydrogel carrier according to Claim 12, wherein the gel comprises at least one compound selected from the group consisting of: acrylic based hydrophilic monomers, crosslinked, polysaccharides and polyols, crosslinked polyethylene glycols, and polyurethane.

15. A method for the administration of charged drugs to the eye comprising:

(i) contacting a substance of the eye with a hydrogel carrier impregnated with said drug;

(ii) passing a current through said carrier at an intensity below about 1000 μ Amp for a period not exceeding 120 seconds and in a direction normal to said surface, thereby causing the charged drug to migrate from said carrier to the eye.

1/2




FIG.1

2/2




FIG.2

INTERNATIONAL SEARCH REPORT

International Application No

PCT/IL 99/00077

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61N1/30

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5 676 648 A (HENLEY JULIAN L) 14 October 1997 see column 3, line 62 - column 5, line 67; figures	1-4, 8, 13
A	WO 96 16693 A (UNIV QUEENSLAND ;ROBERTS MICHAEL STEPHEN (AU); CROSS SHEREE ELIZAB) 6 June 1996 see page 4, line 11 - page 8, line 20; figures	1, 9, 11, 13
A	WO 92 04937 A (HENLEY JULIAN L) 2 April 1992 see page 7, line 1 - page 11, line 1; figures	1, 2, 4, 10, 13
	--- -/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

3 June 1999

Date of mailing of the international search report

11/06/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel: (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Rakotondrajaona, C

INTERNATIONAL SEARCH REPORT

International Application No

PCT/IL 99/00077

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No
A	FR 2 582 946 A (HAYASHIBARA KEN) 12 December 1986 see page 1, line 1 - page 2, line 17; figures	1,8,9
A	WO 92 04938 A (UNIV RUTGERS) 2 April 1992 see page 3, line 4 - page 7, line 4; figures	1,6,8, 11-14

INTERNATIONAL SEARCH REPORT

International application No.

PCT/IL 99/ 00077

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos. 15
because they relate to subject matter not required to be searched by this Authority, namely
Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy
2. ☐ Claims Nos..
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically
3. ☐ Claims Nos..
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a)

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Inter. Jnal Application No

PCT/IL 99/00077

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 5676648	A	14-10-1997	AU 2752797 A WO 9741919 A US 5879323 A	26-11-1997 13-11-1997 09-03-1999
WO 9616693	A	06-06-1996	AU 4111796 A	19-06-1996
WO 9204937	A	02-04-1992	US 5160316 A	03-11-1992
FR 2582946	A	12-12-1986	JP 1635967 C JP 2059746 B JP 61279257 A BR 8602628 A DE 3618933 A GB 2177928 A,B	31-01-1992 13-12-1990 10-12-1986 04-03-1987 11-12-1986 04-02-1987
WO 9204938	A	02-04-1992	US 5250022 A AU 674490 B AU 8904791 A CA 2109092 A EP 0560805 A US 5362308 A	05-10-1993 02-01-1997 15-04-1992 26-03-1992 22-09-1993 08-11-1994